Union Grove, WI, United States of America

Anil Vasudevan

This inventor holds 38 USPTO granted patents and 17 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Abbvie Inc., Abbott Laboratories Corporation, Abbvie Deutschland Gmbh and Co Kg. Active years: 2003-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anil Vasudevan. Retrieved from https://idiyas.com/inventor/anil-vasudevan-ctwhcpn8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 17)

% Patents Active = 55.3

CIPO Patents = 4 (Patent Applications = 22)

EPO Patents = 11 (Patent Applications = 21)

Average Co-Inventor Count = 9.0

ph-index = 6

Forward Citations = 213(Granted Patents)

Location History:

Gurnee, IL (US) (2003 - 2009)
Union Grove, WI (US) (2011 - 2019)
Lake Forest, IL (US) (2019)
North Chicago, IL (US) (2017 - 2020)

Company Filing History:

Abbott Laboratories Corporation

patents

6 out of 167

Abbvie Deutschland Gmbh and Co Kg

patents

where one patent can have more than one assignee

Years Active: 2003-2020

Loading Chart...

Areas of Expertise:

Isoxazolopyridazinones

TNF Signaling

Cyanoguanidines

NAMPT Inhibitors

Kinase Inhibitors

TRPA1 Antagonists

Pyrrolidine Derivatives

Anti-Viral Compounds

Melanin Receptor Antagonists

Histamine-3 Receptor Ligands

Bicyclic Carboxamide

Antiangiogenic Activity

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10556914 - Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use (2020-02-11),

2. 10273238 - Indazolones as modulators of TNF signaling (2019-04-30),

3. 10266532 - Tricyclic modulators of TNF signaling (2019-04-23),

4. 10233179 - Thiazoles and uses thereof (2019-03-19),

5. 10112911 - Substituted cyanoguanidines as oral anti-virals (2018-10-30),

6. 10093624 - NAMPT and ROCK inhibitors (2018-10-09),

7. 9957274 - Indane inhibitors of EED and methods of their use (2018-05-01),

8. 9879016 - Indazolones as modulators of TNF signaling (2018-01-30),

9. 9856253 - Tricyclic modulators of TNF signaling (2018-01-02),

10. 9777020 - Furo-3-carboxamide derivatives and methods of use (2017-10-03),

11. 9751850 - TRPA1 antagonists (2017-09-05),

12. 9656955 - Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-05-23),

13. 9650334 - Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-05-16),

14. 9586945 - Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-03-07),

15. 9586942 - Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-03-07),

Title: Anil Vasudevan: A Pioneer in Pharmaceutical Innovations

Introduction

Anil Vasudevan, based in Union Grove, Wisconsin, has made significant contributions to the field of pharmaceuticals through his remarkable innovation and dedication as an inventor. With an impressive portfolio of 38 patents, he has developed a reputation for creating novel compounds with therapeutic applications.

Latest Patents

Among his latest patents is the development of substituted isoxazolopyridazinones and isothiazolopyridazinones. These compounds, defined by specific formulas, are recognized for their potential to treat conditions that can be prevented or ameliorated by positive allosteric modulation of the gamma-aminobutyric acid B (GABA-B) receptor. Additionally, he has disclosed methods for synthesizing these compounds, alongside pharmaceutical compositions utilizing them.

Another significant patent involves indazolones as modulators of TNF signaling. This patent outlines compounds that are useful in addressing various immunological and oncological conditions. The formulas provided encompass pharmaceutically acceptable salts, pro-drugs, and other biologically active metabolites, underlining the therapeutic potential of these innovations.

Career Highlights

Anil Vasudevan has been affiliated with prominent companies, including AbbVie Inc. and Abbott Laboratories Corporation. His experience at these organizations has allowed him to refine his research skills and contribute to life-changing pharmaceutical innovations.

Collaborations

Throughout his career, Anil has collaborated with esteemed colleagues such as Justin D. Dietrich and Helmut Mack. These partnerships have enabled the sharing of knowledge and expertise, further advancing his research and the development of significant pharmaceutical solutions.

Conclusion

Anil Vasudevan stands out as a leading inventor in the pharmaceutical industry. His extensive patent portfolio showcases his commitment to innovating solutions that address critical health concerns. Through his collaborative efforts and contributions to major pharmaceutical companies, he continues to make a lasting impact on the field.

Profile summary based on public USPTO records.